Effects of clazosentan, cilostazol, and statins on aneurysmal subarachnoid hemorrhage
| العنوان: | Effects of clazosentan, cilostazol, and statins on aneurysmal subarachnoid hemorrhage |
|---|---|
| المؤلفون: | Li Zhang, Yanfei Shen, Junfang He, Yao Yu, Gen Chen, Xinyue Luo, Min Wei |
| المصدر: | Medicine. 99:e19902 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Funnel plot, medicine.medical_specialty, business.industry, MEDLINE, General Medicine, Publication bias, Cochrane Library, law.invention, Cilostazol, 03 medical and health sciences, 0302 clinical medicine, Systematic review, Randomized controlled trial, law, 030220 oncology & carcinogenesis, Meta-analysis, Medicine, 030212 general & internal medicine, business, Intensive care medicine, medicine.drug |
| الوصف: | Background Aneurysmal subarachnoid hemorrhage (aSAH) is a disease caused by the infiltration of blood into the subarachnoid space due to the rupture of an intracranial aneurysm. It is a serious cerebrovascular disease, with a mortality rate of about 40% worldwide, which seriously threatens human life and health. Many drugs are used to treat aSAH and its complications, and some have been tested in systematic reviews and have shown good effects. But which drug has the best effect remains unclear. This network meta-analysis (NMA) aims to assess the effectiveness and feasibility of clazosentan, cilostazol, and statins in patients with aSAH. Methods We will search for EMBASE.com, PubMed, the Cochrane Library, and Web of Science from inception to December 2019. Randomized controlled trials (RCTs) reporting efficacy and safety of clazosentan, cilostazol, and statins compared with the control, or compared with each other for the treatment of aSAH will be included. Two independent reviewers will assess the risk of bias of the included RCTs with the Cochrane "Risk of bias" tool. The pairwise meta-analysis will be performed with the random-effects model. The NMA will be performed in a Bayesian hierarchical framework using Markov Chain Monte Carlo method in WinBUGS 1.4.3. Egger test and funnel plot will be used to assess the publication bias. We will evaluate the quality of evidence for each outcome according to the GRADE approach. Results The results of this NMA will be submitted to a peer-reviewed journal for publication. Conclusion This study will summarize up-to-date evidence to compare the efficacy and safety of clazosentan, cilostazol, and statins on aSAH.PROSPERO registration number: CRD42019147523. |
| تدمد: | 1536-5964 0025-7974 |
| DOI: | 10.1097/md.0000000000019902 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::a08b5eaeeded65c0d23bc8cc02fb7026 https://doi.org/10.1097/md.0000000000019902 |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi...........a08b5eaeeded65c0d23bc8cc02fb7026 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15365964 00257974 |
|---|---|
| DOI: | 10.1097/md.0000000000019902 |